FTO overexpression in breast cancer is implicated in promoting tumor aggressiveness, whereas epitranscriptomic profiling of peripheral blood RNA has identified m6A modifications as novel noninvasive diagnostic biomarkers. This evidence concerns the gene FTO and neoplasm.